With an investment in Travel Health Group (THG), BB Capital has taken an interest in the company. The investment gives THG the opportunity to stay market leader in anti-insects and travel healthcare and innovate.
International growth and European expansion
THG offers with Tropicare and premium brand Care Plus a complete range of health protection for travellers. The injection should help expand the foreign activities. THG is known from the EU-registered DEET and anti-insect products and impregnated mosquito nets to prevent from malaria and infections. The Care Plus products are already available in Europe via various retailers and an international webshop. The most popular products are even available as white label. “We are unique with our 7 registered DEET-formulas in Europe. Those USP’s will help us grow our revenue from 10 million to at least double” says Arnoud Aalbersberg, CEO.
“The Travel Health Group is a business with ambitious goals and proven results. Combined with the serious social awareness and the management qualities, those where the pillars on which we made the decision to invest,” says Susan van Koeveringe from BB Capital Investments. The The Hague based fund is in line with other impact investments the fund recently made.